International SSRI Pharmacogenomics Consortium (ISPC) Phenotype Data
Abstract/Contents
- Abstract
- Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably between patients. The International SSRI Pharmacogenomics Consortium (ISPC) was formed with the primary goal of identifying genetic variation that may contribute to response to SSRI treatment of major depressive disorder. A genome-wide association study of 4-week treatment outcomes, measured using the 17-item Hamilton Rating Scale for Depression (HRSD-17), was performed using data from 865 subjects from seven sites. The primary outcomes were percent change in HRSD-17 score and response, defined as at least 50% reduction in HRSD-17. Data from two prior studies, the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomics Study (PGRN-AMPS) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, were used for replication, and a meta-analysis of the three studies was performed (N=2394). Although many top association signals in the ISPC analysis map to interesting candidate genes, none were significant at the genome-wide level and the associations were not replicated using PGRN-AMPS and STAR*D data. The top association result in the meta-analysis of response represents SNPs 5′ upstream of the neuregulin-1 gene, NRG1 (P = 1.20E - 06). NRG1 is involved in many aspects of brain development, including neuronal maturation and variations in this gene have been shown to be associated with increased risk for mental disorders, particularly schizophrenia. Replication and functional studies of these findings are warranted.
Description
| Type of resource | software, multimedia |
|---|---|
| Date created | April 21, 2015 |
Creators/Contributors
| Author | International SSRI Pharmacogenomics Consortium |
|---|
Subjects
| Subject | pharmacogenetics |
|---|---|
| Subject | Department of Biomedical Data Science |
| Subject | School of Medicine |
| Subject | PharmGKB |
| Genre | Dataset |
Bibliographic information
| Related Publication | Biernacka JM, Sangkuhl K, Jenkins G, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response [published correction appears in Transl Psychiatry. 2016 Nov 1;6(11):e937]. Transl Psychiatry. 2015;5(4):e553. Published 2015 Apr 21. doi:10.1038/tp.2015.47 |
|---|---|
| Related item |
|
| Location | https://purl.stanford.edu/bg091gk8548 |
Access conditions
- Use and reproduction
- User agrees that, where applicable, content will not be used to identify or to otherwise infringe the privacy or confidentiality rights of individuals. Content distributed via the Stanford Digital Repository may be subject to additional license and use restrictions applied by the depositor.
Preferred citation
- Preferred Citation
- Biernacka JM, Sangkuhl K, Jenkins G, et al. (2015). International SSRI Pharmacogenomics Consortium (ISPC) Phenotype Data. Stanford Digital Repository. Available at: https://purl.stanford.edu/bg091gk8548
Collection
The Helix Group
Contact information
- Contact
- feedback@pharmgkb.org
Also listed in
Loading usage metrics...